Launching of new prescription pain treatment to be delayed

Janssen Korea says Jurnista prolonged-release tablets (hydromorphone HCl), a new prescription treatment for severe pain, will not be available on market in September, as its price negotiation with the National Health Insurance Corp. failed.

The assessment is likely to take time since Janssen Korea is calling for a more profitable price, while the NHIC is asking for something that is affordab...